INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1201, 23610, 'Ixazomib', 'Hepatic Insufficiency', 'Pharmacokinetic studies of ixazomib in patients with moderate to severe hepatic impairment, showed an increase AUC when compared to patients with normal hepatic function.  The pharmacokinetic of ixazomib was similar in patients with normal hepatic function and in patients with mild hepatic impairment.  It is recommended to reduce the starting dose in patients with moderate to severe hepatic impairment.  Caution should be exercised when ixazomib is administered to patients with moderate to severe hepatic function and monitoring of liver function tests is recommended as appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1202, 23608, 'Ixazomib', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported with the use of ixazomib.  Patients should be monitored for symptoms of neuropathy and if they are experiencing new or worsening peripheral neuropathy, it is recommended to withhold therapy and modify the dose as per manufacturer instructions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1203, 23609, 'Ixazomib', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported with the use of ixazomib.  Patients should be monitored for symptoms of neuropathy and if they are experiencing new or worsening peripheral neuropathy, it is recommended to withhold therapy and modify the dose as per manufacturer instructions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1204, 23610, 'Ixazomib', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported with the use of ixazomib.  Patients should be monitored for symptoms of neuropathy and if they are experiencing new or worsening peripheral neuropathy, it is recommended to withhold therapy and modify the dose as per manufacturer instructions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1205, 23608, 'Ixazomib', 'Kidney Diseases', 'Population PK analysis in patients with severe renal impairment or ESRD requiring dialysis showed an increase AUC when compared to patients with normal renal function.  The pharmacokinetic of ixazomib was similar in patients with normal renal function and in patients with mild or moderate renal impairment.  It is recommended to reduce the starting dose in patients with severe renal impairment or ESRD requiring dialysis.  Caution should be exercised when ixazomib is administered to patients with severe renal impairment.  Ixazomib is not dialyzable and therefore can be administered without regard to the timing of dialysis', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1206, 23609, 'Ixazomib', 'Kidney Diseases', 'Population PK analysis in patients with severe renal impairment or ESRD requiring dialysis showed an increase AUC when compared to patients with normal renal function.  The pharmacokinetic of ixazomib was similar in patients with normal renal function and in patients with mild or moderate renal impairment.  It is recommended to reduce the starting dose in patients with severe renal impairment or ESRD requiring dialysis.  Caution should be exercised when ixazomib is administered to patients with severe renal impairment.  Ixazomib is not dialyzable and therefore can be administered without regard to the timing of dialysis', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1207, 23610, 'Ixazomib', 'Kidney Diseases', 'Population PK analysis in patients with severe renal impairment or ESRD requiring dialysis showed an increase AUC when compared to patients with normal renal function.  The pharmacokinetic of ixazomib was similar in patients with normal renal function and in patients with mild or moderate renal impairment.  It is recommended to reduce the starting dose in patients with severe renal impairment or ESRD requiring dialysis.  Caution should be exercised when ixazomib is administered to patients with severe renal impairment.  Ixazomib is not dialyzable and therefore can be administered without regard to the timing of dialysis', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1208, 23608, 'Ixazomib', 'Thrombocytopenia', 'Thrombocytopenia has been reported with the use of ixazomib.  It is recommended to monitor platelet counts regularly during treatment and to considered withholding therapy or dosage modifications and platelet transfusions as per manufacturer recommendations and clinical guidelines.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1209, 23609, 'Ixazomib', 'Thrombocytopenia', 'Thrombocytopenia has been reported with the use of ixazomib.  It is recommended to monitor platelet counts regularly during treatment and to considered withholding therapy or dosage modifications and platelet transfusions as per manufacturer recommendations and clinical guidelines.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1210, 23610, 'Ixazomib', 'Thrombocytopenia', 'Thrombocytopenia has been reported with the use of ixazomib.  It is recommended to monitor platelet counts regularly during treatment and to considered withholding therapy or dosage modifications and platelet transfusions as per manufacturer recommendations and clinical guidelines.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1211, 3592, 'Kanamycin', 'Dehydration', 'Adequate hydration is crucial to minimize the risk of oto- and nephrotoxicity associated with the use of aminoglycosides.  Dehydration should preferably be corrected prior to initiation of therapy.  In patients who may be at risk for dehydration, such as those with severe and/or prolonged diarrhea or vomiting, fluid status should be monitored closely.  If signs of renal irritation develop during therapy, hydration should be increased as indicated, accompanied by a reduction in dosage if necessary.  Therapy should be withdrawn if urinary output decreases progressively or azotemia increases.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1212, 3592, 'Kanamycin', 'Neuromuscular Diseases', 'Aminoglycosides can cause dose-related neuromuscular blockade and muscle weakness, particularly in patients with neuromuscular disease or hypocalcemia and in patients receiving general anesthetics, neuromuscular blocking agents, or massive transfusions of citrate-anticoagulated blood.  Although aminoglycoside- induced neuromuscular blockade is generally self-limiting, it may rarely result in respiratory paralysis.  Neomycin is thought to be the most potent neuromuscular blocking agent in the class.  However, the risk is greatest with intraperitoneal or intrapleural instillation of large doses or rapid intravenous administration of parenteral aminoglycosides.  Therapy with aminoglycosides should be administered cautiously in patients with neuromuscular disorders (e.g., myasthenia gravis, parkinsonian syndrome, botulism) or hypocalcemia.  If signs of respiratory paralysis occur during aminoglycoside therapy, the drug should be discontinued and mechanical respiratory assistance provided if necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1213, 3592, 'Kanamycin', 'Ototoxicity', 'Aminoglycosides can cause eighth cranial nerve damage, resulting in vestibular and/or auditory toxicities.  Symptoms include dizziness, nystagmus, vertigo, ataxia, tinnitus, and varying degrees of hearing impairment.  Permanent hearing loss may occur, including, rarely, total or partial irreversible bilateral deafness after the drug has been discontinued.  Therapy with aminoglycosides, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting vestibular and/or auditory impairment, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, patients should be adequately hydrated, the usual aminoglycoside dosage should not be exceeded, use with other ototoxic agents should be avoided, and peak and trough serum aminoglycoside concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Serial audiograms should be obtained in patients old enough to be tested, since loss of high- frequency perception usually precedes clinical hearing loss.  The dosage should be reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1214, 3592, 'Kanamycin', 'Kidney Diseases', 'Aminoglycosides are potentially oto- and nephrotoxic.  Eighth cranial nerve damage may manifest as vestibular and/or auditory toxicities, including dizziness, nystagmus, vertigo, ataxia, tinnitus, and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by tubular necrosis; increases in BUN, nonprotein nitrogen, and serum creatinine concentration; decreases in urine specific gravity and creatinine clearance; proteinuria; and cells or casts in the urine.  Rarely, renal electrolyte wasting may occur, resulting in hypocalcemia, hypomagnesemia, and hypokalemia that may be associated with paresthesia, tetany, confusion, and positive Chvostek and Trousseau signs.  Although aminoglycoside- induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred rarely.  Therapy with aminoglycosides should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, patients should be adequately hydrated, the usual aminoglycoside dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and peak and trough serum aminoglycoside concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1215, 3592, 'Kanamycin', 'Intestinal Obstruction', 'The use of oral aminoglycosides is contraindicated in patients with intestinal obstruction.  Orally administered aminoglycosides are poorly absorbed from the gastrointestinal tract and primarily eliminated unchanged in the feces.  Drug retention and enhanced systemic absorption may occur in the presence of intestinal obstruction, increasing the risk of oto- and nephrotoxicity associated with these drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1216, 3592, 'Kanamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1217, 3182, 'Ketoconazole', 'Liver Diseases', 'Serious hepatotoxicity including cases with a fatal outcome or requiring liver transplant have been reported.  Some patients had no obvious risk factors for liver disease.  Liver function tests should be performed prior to initiation of therapy and regularly during treatment in patients receiving prolonged therapy with ketoconazole, particularly those with a current or past history of liver disease.  Therapy should be withdrawn if persistent elevations or worsening of liver enzyme levels occur, or if the abnormalities are accompanied by symptoms of possible liver injury.  Since ketoconazole is primarily metabolized by the liver, empirically reducing the dosage may also be appropriate in patients with existing liver disease.  The use of oral ketoconazole tablets is contraindicated in patients with acute or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1218, 6867, 'Ketoconazole', 'Liver Diseases', 'Serious hepatotoxicity including cases with a fatal outcome or requiring liver transplant have been reported.  Some patients had no obvious risk factors for liver disease.  Liver function tests should be performed prior to initiation of therapy and regularly during treatment in patients receiving prolonged therapy with ketoconazole, particularly those with a current or past history of liver disease.  Therapy should be withdrawn if persistent elevations or worsening of liver enzyme levels occur, or if the abnormalities are accompanied by symptoms of possible liver injury.  Since ketoconazole is primarily metabolized by the liver, empirically reducing the dosage may also be appropriate in patients with existing liver disease.  The use of oral ketoconazole tablets is contraindicated in patients with acute or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1219, 6868, 'Ketoconazole', 'Liver Diseases', 'Serious hepatotoxicity including cases with a fatal outcome or requiring liver transplant have been reported.  Some patients had no obvious risk factors for liver disease.  Liver function tests should be performed prior to initiation of therapy and regularly during treatment in patients receiving prolonged therapy with ketoconazole, particularly those with a current or past history of liver disease.  Therapy should be withdrawn if persistent elevations or worsening of liver enzyme levels occur, or if the abnormalities are accompanied by symptoms of possible liver injury.  Since ketoconazole is primarily metabolized by the liver, empirically reducing the dosage may also be appropriate in patients with existing liver disease.  The use of oral ketoconazole tablets is contraindicated in patients with acute or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1220, 6869, 'Ketoconazole', 'Liver Diseases', 'Serious hepatotoxicity including cases with a fatal outcome or requiring liver transplant have been reported.  Some patients had no obvious risk factors for liver disease.  Liver function tests should be performed prior to initiation of therapy and regularly during treatment in patients receiving prolonged therapy with ketoconazole, particularly those with a current or past history of liver disease.  Therapy should be withdrawn if persistent elevations or worsening of liver enzyme levels occur, or if the abnormalities are accompanied by symptoms of possible liver injury.  Since ketoconazole is primarily metabolized by the liver, empirically reducing the dosage may also be appropriate in patients with existing liver disease.  The use of oral ketoconazole tablets is contraindicated in patients with acute or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1221, 8908, 'Ketoconazole', 'Liver Diseases', 'Serious hepatotoxicity including cases with a fatal outcome or requiring liver transplant have been reported.  Some patients had no obvious risk factors for liver disease.  Liver function tests should be performed prior to initiation of therapy and regularly during treatment in patients receiving prolonged therapy with ketoconazole, particularly those with a current or past history of liver disease.  Therapy should be withdrawn if persistent elevations or worsening of liver enzyme levels occur, or if the abnormalities are accompanied by symptoms of possible liver injury.  Since ketoconazole is primarily metabolized by the liver, empirically reducing the dosage may also be appropriate in patients with existing liver disease.  The use of oral ketoconazole tablets is contraindicated in patients with acute or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1222, 8914, 'Ketoconazole', 'Liver Diseases', 'Serious hepatotoxicity including cases with a fatal outcome or requiring liver transplant have been reported.  Some patients had no obvious risk factors for liver disease.  Liver function tests should be performed prior to initiation of therapy and regularly during treatment in patients receiving prolonged therapy with ketoconazole, particularly those with a current or past history of liver disease.  Therapy should be withdrawn if persistent elevations or worsening of liver enzyme levels occur, or if the abnormalities are accompanied by symptoms of possible liver injury.  Since ketoconazole is primarily metabolized by the liver, empirically reducing the dosage may also be appropriate in patients with existing liver disease.  The use of oral ketoconazole tablets is contraindicated in patients with acute or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1223, 8916, 'Ketoconazole', 'Liver Diseases', 'Serious hepatotoxicity including cases with a fatal outcome or requiring liver transplant have been reported.  Some patients had no obvious risk factors for liver disease.  Liver function tests should be performed prior to initiation of therapy and regularly during treatment in patients receiving prolonged therapy with ketoconazole, particularly those with a current or past history of liver disease.  Therapy should be withdrawn if persistent elevations or worsening of liver enzyme levels occur, or if the abnormalities are accompanied by symptoms of possible liver injury.  Since ketoconazole is primarily metabolized by the liver, empirically reducing the dosage may also be appropriate in patients with existing liver disease.  The use of oral ketoconazole tablets is contraindicated in patients with acute or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1224, 8919, 'Ketoconazole', 'Liver Diseases', 'Serious hepatotoxicity including cases with a fatal outcome or requiring liver transplant have been reported.  Some patients had no obvious risk factors for liver disease.  Liver function tests should be performed prior to initiation of therapy and regularly during treatment in patients receiving prolonged therapy with ketoconazole, particularly those with a current or past history of liver disease.  Therapy should be withdrawn if persistent elevations or worsening of liver enzyme levels occur, or if the abnormalities are accompanied by symptoms of possible liver injury.  Since ketoconazole is primarily metabolized by the liver, empirically reducing the dosage may also be appropriate in patients with existing liver disease.  The use of oral ketoconazole tablets is contraindicated in patients with acute or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1225, 12764, 'Ketoconazole', 'Liver Diseases', 'Serious hepatotoxicity including cases with a fatal outcome or requiring liver transplant have been reported.  Some patients had no obvious risk factors for liver disease.  Liver function tests should be performed prior to initiation of therapy and regularly during treatment in patients receiving prolonged therapy with ketoconazole, particularly those with a current or past history of liver disease.  Therapy should be withdrawn if persistent elevations or worsening of liver enzyme levels occur, or if the abnormalities are accompanied by symptoms of possible liver injury.  Since ketoconazole is primarily metabolized by the liver, empirically reducing the dosage may also be appropriate in patients with existing liver disease.  The use of oral ketoconazole tablets is contraindicated in patients with acute or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1226, 12765, 'Ketoconazole', 'Liver Diseases', 'Serious hepatotoxicity including cases with a fatal outcome or requiring liver transplant have been reported.  Some patients had no obvious risk factors for liver disease.  Liver function tests should be performed prior to initiation of therapy and regularly during treatment in patients receiving prolonged therapy with ketoconazole, particularly those with a current or past history of liver disease.  Therapy should be withdrawn if persistent elevations or worsening of liver enzyme levels occur, or if the abnormalities are accompanied by symptoms of possible liver injury.  Since ketoconazole is primarily metabolized by the liver, empirically reducing the dosage may also be appropriate in patients with existing liver disease.  The use of oral ketoconazole tablets is contraindicated in patients with acute or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1227, 21326, 'Ketoconazole', 'Liver Diseases', 'Serious hepatotoxicity including cases with a fatal outcome or requiring liver transplant have been reported.  Some patients had no obvious risk factors for liver disease.  Liver function tests should be performed prior to initiation of therapy and regularly during treatment in patients receiving prolonged therapy with ketoconazole, particularly those with a current or past history of liver disease.  Therapy should be withdrawn if persistent elevations or worsening of liver enzyme levels occur, or if the abnormalities are accompanied by symptoms of possible liver injury.  Since ketoconazole is primarily metabolized by the liver, empirically reducing the dosage may also be appropriate in patients with existing liver disease.  The use of oral ketoconazole tablets is contraindicated in patients with acute or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1228, 21481, 'Ketoconazole', 'Liver Diseases', 'Serious hepatotoxicity including cases with a fatal outcome or requiring liver transplant have been reported.  Some patients had no obvious risk factors for liver disease.  Liver function tests should be performed prior to initiation of therapy and regularly during treatment in patients receiving prolonged therapy with ketoconazole, particularly those with a current or past history of liver disease.  Therapy should be withdrawn if persistent elevations or worsening of liver enzyme levels occur, or if the abnormalities are accompanied by symptoms of possible liver injury.  Since ketoconazole is primarily metabolized by the liver, empirically reducing the dosage may also be appropriate in patients with existing liver disease.  The use of oral ketoconazole tablets is contraindicated in patients with acute or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1229, 21482, 'Ketoconazole', 'Liver Diseases', 'Serious hepatotoxicity including cases with a fatal outcome or requiring liver transplant have been reported.  Some patients had no obvious risk factors for liver disease.  Liver function tests should be performed prior to initiation of therapy and regularly during treatment in patients receiving prolonged therapy with ketoconazole, particularly those with a current or past history of liver disease.  Therapy should be withdrawn if persistent elevations or worsening of liver enzyme levels occur, or if the abnormalities are accompanied by symptoms of possible liver injury.  Since ketoconazole is primarily metabolized by the liver, empirically reducing the dosage may also be appropriate in patients with existing liver disease.  The use of oral ketoconazole tablets is contraindicated in patients with acute or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1230, 21483, 'Ketoconazole', 'Liver Diseases', 'Serious hepatotoxicity including cases with a fatal outcome or requiring liver transplant have been reported.  Some patients had no obvious risk factors for liver disease.  Liver function tests should be performed prior to initiation of therapy and regularly during treatment in patients receiving prolonged therapy with ketoconazole, particularly those with a current or past history of liver disease.  Therapy should be withdrawn if persistent elevations or worsening of liver enzyme levels occur, or if the abnormalities are accompanied by symptoms of possible liver injury.  Since ketoconazole is primarily metabolized by the liver, empirically reducing the dosage may also be appropriate in patients with existing liver disease.  The use of oral ketoconazole tablets is contraindicated in patients with acute or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1231, 29644, 'Ketoconazole', 'Liver Diseases', 'Serious hepatotoxicity including cases with a fatal outcome or requiring liver transplant have been reported.  Some patients had no obvious risk factors for liver disease.  Liver function tests should be performed prior to initiation of therapy and regularly during treatment in patients receiving prolonged therapy with ketoconazole, particularly those with a current or past history of liver disease.  Therapy should be withdrawn if persistent elevations or worsening of liver enzyme levels occur, or if the abnormalities are accompanied by symptoms of possible liver injury.  Since ketoconazole is primarily metabolized by the liver, empirically reducing the dosage may also be appropriate in patients with existing liver disease.  The use of oral ketoconazole tablets is contraindicated in patients with acute or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1232, 3182, 'Ketoconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1233, 6867, 'Ketoconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1234, 6868, 'Ketoconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1235, 6869, 'Ketoconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1236, 8908, 'Ketoconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1237, 8914, 'Ketoconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1238, 8916, 'Ketoconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1239, 8919, 'Ketoconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1240, 12764, 'Ketoconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1241, 12765, 'Ketoconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1242, 21326, 'Ketoconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1243, 21481, 'Ketoconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1244, 21482, 'Ketoconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1245, 21483, 'Ketoconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1246, 29644, 'Ketoconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1247, 3182, 'Ketoconazole', 'Achlorhydria', 'Nizoral (brand of ketoconazole) tablets require acidity for proper dissolution and absorption.  Therefore, the drug may not be effective in patients with achlorhydria.  Taking the medication with an acidic beverage such as orange or cranberry juice may help, but an alternative antifungal agent should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1248, 6867, 'Ketoconazole', 'Achlorhydria', 'Nizoral (brand of ketoconazole) tablets require acidity for proper dissolution and absorption.  Therefore, the drug may not be effective in patients with achlorhydria.  Taking the medication with an acidic beverage such as orange or cranberry juice may help, but an alternative antifungal agent should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1249, 6868, 'Ketoconazole', 'Achlorhydria', 'Nizoral (brand of ketoconazole) tablets require acidity for proper dissolution and absorption.  Therefore, the drug may not be effective in patients with achlorhydria.  Taking the medication with an acidic beverage such as orange or cranberry juice may help, but an alternative antifungal agent should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1250, 6869, 'Ketoconazole', 'Achlorhydria', 'Nizoral (brand of ketoconazole) tablets require acidity for proper dissolution and absorption.  Therefore, the drug may not be effective in patients with achlorhydria.  Taking the medication with an acidic beverage such as orange or cranberry juice may help, but an alternative antifungal agent should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1251, 8908, 'Ketoconazole', 'Achlorhydria', 'Nizoral (brand of ketoconazole) tablets require acidity for proper dissolution and absorption.  Therefore, the drug may not be effective in patients with achlorhydria.  Taking the medication with an acidic beverage such as orange or cranberry juice may help, but an alternative antifungal agent should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1252, 8914, 'Ketoconazole', 'Achlorhydria', 'Nizoral (brand of ketoconazole) tablets require acidity for proper dissolution and absorption.  Therefore, the drug may not be effective in patients with achlorhydria.  Taking the medication with an acidic beverage such as orange or cranberry juice may help, but an alternative antifungal agent should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1253, 8916, 'Ketoconazole', 'Achlorhydria', 'Nizoral (brand of ketoconazole) tablets require acidity for proper dissolution and absorption.  Therefore, the drug may not be effective in patients with achlorhydria.  Taking the medication with an acidic beverage such as orange or cranberry juice may help, but an alternative antifungal agent should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1254, 8919, 'Ketoconazole', 'Achlorhydria', 'Nizoral (brand of ketoconazole) tablets require acidity for proper dissolution and absorption.  Therefore, the drug may not be effective in patients with achlorhydria.  Taking the medication with an acidic beverage such as orange or cranberry juice may help, but an alternative antifungal agent should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1255, 12764, 'Ketoconazole', 'Achlorhydria', 'Nizoral (brand of ketoconazole) tablets require acidity for proper dissolution and absorption.  Therefore, the drug may not be effective in patients with achlorhydria.  Taking the medication with an acidic beverage such as orange or cranberry juice may help, but an alternative antifungal agent should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1256, 12765, 'Ketoconazole', 'Achlorhydria', 'Nizoral (brand of ketoconazole) tablets require acidity for proper dissolution and absorption.  Therefore, the drug may not be effective in patients with achlorhydria.  Taking the medication with an acidic beverage such as orange or cranberry juice may help, but an alternative antifungal agent should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1257, 21326, 'Ketoconazole', 'Achlorhydria', 'Nizoral (brand of ketoconazole) tablets require acidity for proper dissolution and absorption.  Therefore, the drug may not be effective in patients with achlorhydria.  Taking the medication with an acidic beverage such as orange or cranberry juice may help, but an alternative antifungal agent should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1258, 21481, 'Ketoconazole', 'Achlorhydria', 'Nizoral (brand of ketoconazole) tablets require acidity for proper dissolution and absorption.  Therefore, the drug may not be effective in patients with achlorhydria.  Taking the medication with an acidic beverage such as orange or cranberry juice may help, but an alternative antifungal agent should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1259, 21482, 'Ketoconazole', 'Achlorhydria', 'Nizoral (brand of ketoconazole) tablets require acidity for proper dissolution and absorption.  Therefore, the drug may not be effective in patients with achlorhydria.  Taking the medication with an acidic beverage such as orange or cranberry juice may help, but an alternative antifungal agent should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1260, 21483, 'Ketoconazole', 'Achlorhydria', 'Nizoral (brand of ketoconazole) tablets require acidity for proper dissolution and absorption.  Therefore, the drug may not be effective in patients with achlorhydria.  Taking the medication with an acidic beverage such as orange or cranberry juice may help, but an alternative antifungal agent should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1261, 29644, 'Ketoconazole', 'Achlorhydria', 'Nizoral (brand of ketoconazole) tablets require acidity for proper dissolution and absorption.  Therefore, the drug may not be effective in patients with achlorhydria.  Taking the medication with an acidic beverage such as orange or cranberry juice may help, but an alternative antifungal agent should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1262, 3182, 'Ketoconazole', 'Adrenal Insufficiency', 'Ketoconazole tablets decrease adrenal corticosteroid secretion at doses of 400 mg and higher.  Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intensive care, etc.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1263, 6867, 'Ketoconazole', 'Adrenal Insufficiency', 'Ketoconazole tablets decrease adrenal corticosteroid secretion at doses of 400 mg and higher.  Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intensive care, etc.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1264, 6868, 'Ketoconazole', 'Adrenal Insufficiency', 'Ketoconazole tablets decrease adrenal corticosteroid secretion at doses of 400 mg and higher.  Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intensive care, etc.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1265, 6869, 'Ketoconazole', 'Adrenal Insufficiency', 'Ketoconazole tablets decrease adrenal corticosteroid secretion at doses of 400 mg and higher.  Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intensive care, etc.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1266, 8908, 'Ketoconazole', 'Adrenal Insufficiency', 'Ketoconazole tablets decrease adrenal corticosteroid secretion at doses of 400 mg and higher.  Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intensive care, etc.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1267, 8914, 'Ketoconazole', 'Adrenal Insufficiency', 'Ketoconazole tablets decrease adrenal corticosteroid secretion at doses of 400 mg and higher.  Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intensive care, etc.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1268, 8916, 'Ketoconazole', 'Adrenal Insufficiency', 'Ketoconazole tablets decrease adrenal corticosteroid secretion at doses of 400 mg and higher.  Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intensive care, etc.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1269, 8919, 'Ketoconazole', 'Adrenal Insufficiency', 'Ketoconazole tablets decrease adrenal corticosteroid secretion at doses of 400 mg and higher.  Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intensive care, etc.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1270, 12764, 'Ketoconazole', 'Adrenal Insufficiency', 'Ketoconazole tablets decrease adrenal corticosteroid secretion at doses of 400 mg and higher.  Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intensive care, etc.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1271, 12765, 'Ketoconazole', 'Adrenal Insufficiency', 'Ketoconazole tablets decrease adrenal corticosteroid secretion at doses of 400 mg and higher.  Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intensive care, etc.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1272, 21326, 'Ketoconazole', 'Adrenal Insufficiency', 'Ketoconazole tablets decrease adrenal corticosteroid secretion at doses of 400 mg and higher.  Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intensive care, etc.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1273, 21481, 'Ketoconazole', 'Adrenal Insufficiency', 'Ketoconazole tablets decrease adrenal corticosteroid secretion at doses of 400 mg and higher.  Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intensive care, etc.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1274, 21482, 'Ketoconazole', 'Adrenal Insufficiency', 'Ketoconazole tablets decrease adrenal corticosteroid secretion at doses of 400 mg and higher.  Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intensive care, etc.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1275, 21483, 'Ketoconazole', 'Adrenal Insufficiency', 'Ketoconazole tablets decrease adrenal corticosteroid secretion at doses of 400 mg and higher.  Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intensive care, etc.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1276, 29644, 'Ketoconazole', 'Adrenal Insufficiency', 'Ketoconazole tablets decrease adrenal corticosteroid secretion at doses of 400 mg and higher.  Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intensive care, etc.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1277, 0, 'Ivosidenib', 'Long QT Syndrome', 'Patients treated with ivosidenib can develop QTc prolongation and ventricular arrhythmias.  Concomitant use of ivosidenib with drugs known to prolong the QTc interval (e.g., antiarrhythmic medicines, fluoroquinolones, triazole antifungals, 5-HT3 receptor antagonists) and CYP3A4 inhibitors may increase the risk of QTc interval prolongation.  Conduct monitoring of electrocardiograms (ECGs) and electrolytes.  In patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval, more frequent monitoring may be necessary.  Treatment should be interrupted or dose reduced if QTc increases to greater than 480 msec.  Permanently discontinue ivosidenib in patients who develop QTc interval prolongation with signs or symptoms of life-threatening arrhythmia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1278, 0, 'Ivosidenib', 'Liver Failure', 'The pharmacokinetics of ivosidenib in patients with severe renal impairment (eGFR <30 mL/min/1.73m2,), renal impairment requiring dialysis, moderate hepatic impairment (total bilirubin 1.5 to 3.0 times the ULN and any value for AST), or severe hepatic impairment (total bilirubin greater than 3.0 times the ULN and any value for AST) is unknown.  Caution is advised if using in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1279, 7040, 'Lactobacillus acidophilus', 'IMMUNE SUPPRESSION', 'Probiotics, especially those containing lactobacillus, should be used with caution in immunosuppressed patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1280, 7486, 'Lactobacillus acidophilus', 'IMMUNE SUPPRESSION', 'Probiotics, especially those containing lactobacillus, should be used with caution in immunosuppressed patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1281, 0, 'Abacavir', 'Liver Diseases', 'Hepatotoxicity including lactic acidosis, severe hepatomegaly with steatosis, fulminant hepatitis, and hepatic failure has been associated with the use of some nucleoside reverse transcriptase inhibitors (NRTIs) alone or in combination with other antiretroviral agents.  Therapy with NRTIs should be administered cautiously in patients with preexisting liver disease, a history of alcohol abuse, or hepatitis.  Therapy should be suspended if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.  The use of abacavir is contraindicated in patients with moderate to severe hepatic impairment as its safety and efficacy has not been established on these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1282, 0, 'Abacavir', 'Cardiovascular Diseases', 'Some clinical trials have reported increased risk of myocardial infarction in patients treated with abacavir.  Although some of the findings are inconclusive, as a precaution, the underlying risk of coronary heart disease should be assessed before therapy, and action should be taken to minimize all modifiable risk factors such as hypertension, hyperlipidemia, diabetes mellitus, smoking, etc.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1283, 0, 'Ixabepilone', 'Pancytopenia', 'Ixabepilone is contraindicated in patients who have a neutrophil count <1500 cells/mm3 or a platelet count <100,000 cells/mm3.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1284, 0, 'Ixabepilone', 'Liver Diseases', 'The use of ixabepilone in combination with capecitabine is contraindicated in patients with AST or ALT >2.5 x ULN or bilirubin >1 x ULN due to increased risk of toxicity and neutropenia-related death.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1285, 0, 'Ixabepilone', 'Cardiovascular Diseases', 'The use of ixabepilone in combination with capecitabine may increase cardiac adverse reactions, such as myocardial ischemia and ventricular dysfunction.  Care should be exercised when using this agent in combination with capecitabine in patients with a history of cardiac disease.  It is recommended to discontinue treatment in patients who develop cardiac ischemia or impaired cardiac function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1286, 0, 'Ixabepilone', 'Peripheral Nervous System Diseases', 'The use of ixabepilone in combination with capecitabine may cause peripheral neuropathy.  Patients treated with ixabepilone in combination with capecitabine should be monitored for symptoms of neuropathy.  Patients experiencing new or worsening symptoms may require a reduction or delay in the dose.  Caution should be used when treating patients with diabetes mellitus or preexisting peripheral neuropathy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1287, 0, 'Antihemophilic factor, human recombinant', 'Cardiovascular Diseases', 'Hemophilic patients with cardiovascular risk factors or diseases may be at the same risk to develop cardiovascular events as non-hemophilic patients when clotting has been normalized by treatment with factor VIII.  Care should be exercised when using this agent in patients with cardiovascular risk factors.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1288, 0, 'Antihemophilic factor, human recombinant', 'Anemia, Hemolytic', 'Blood group isoagglutinins (anti-A and anti-B) are present in antihemophilic factor (human) at concentrations that may not be clinically significant when used to control minor bleeds.  Monitoring of hematocrit and Coombs for signs of intravascular hemolysis and falling hematocrit is recommended in patients with blood groups A, B, or AB when large or frequently repeated doses of antihemophilic factor (human) are administered.  Acute hemolytic anemia may occur, resulting in increased bleeding tendency or hyperfibrinogenemia.  Should this condition occur, leading to progressive hemolytic anemia, discontinue treatment and consider administering serologically compatible Type O red blood cells and providing alternative therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1289, 0, 'Antihemophilic factor, human recombinant', 'Immune Deficiency Disease', 'Because antihemophilic factor (human) is made from human blood, it may carry a risk of transmitting infectious agents.  The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by inactivating and/or removing certain viruses during the manufacturing process.  The risk of transmission of infectious agents cannot be eliminated completely.  Some viruses, such as Parvovirus B19 virus (B19V) or hepatitis A (HAV), are particularly difficult to remove or inactivate.  B19V may most seriously affect pregnant women and immune-compromised individuals.  Physicians should be alert to the potential symptoms of B19V and HAV infections and should strongly consider administration of hepatitis A and hepatitis B vaccines to individuals receiving plasma derivatives.  Potential risks and benefits of vaccination should be weighed by the physician and discussed with the patient.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1290, 0, 'Antihemophilic factor, human recombinant', 'Thromboembolism', 'Thromboembolic events have been reported in patients receiving antihemophilic factor/von Willebrand factor complex replacement therapy.  Care should be exercised in the existence of known risk factors for thrombosis.  Endogenous high levels of factor VIII have also been associated with thrombosis, but no causal relationship has been established.  Caution is recommended and consider antithrombotic measures in all patients at risk who are receiving coagulation factor replacement therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1291, 3008, 'Lamotrigine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1292, 3010, 'Lamotrigine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1293, 3011, 'Lamotrigine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1294, 4022, 'Lamotrigine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1295, 4024, 'Lamotrigine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1296, 4032, 'Lamotrigine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1297, 7074, 'Lamotrigine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1298, 7075, 'Lamotrigine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1299, 7088, 'Lamotrigine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (1300, 7089, 'Lamotrigine', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '', 'DDInter', 0);
